Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm buying here in the $4.8's. :)
bio_pete, was this the last JAV selling hairball??
http://finance.yahoo.com/q/bc?s=JAV&t=1d
looks like JAV is finally on the mend.
Not sure what Nerf meant by price dropping last time. I believe he meant for the June options expiration, not the drop from 15 high back down to 12-13's level. Someone sold during last June options expiration during the last hour on a Friday. Knocked the price down 50-60 cents if I remember right. anyhooo, we may be facing this gamemanship again later this week. Anything can happen.
bio_pete....nope, I'm just letting you know I'm getting aboard JAV. Hopefully my patience will pay off. regn getting whacked pretty good today too. maybe it was that other competitors AMD trial Dew mentioned causing the sell off? Or is it the $17.5 strike options! those SOBs. ;)
Have a good one -- going albacore fishing off Oregon coast tomorrow morning. Albacore are running very heavy here as waters warmed from usual 52's F to 63 F range. San Diego temps up north and so are the fish! ><))))))*>
Spartex
I just picked up 6000 shares at 5.49 over the past 1/2 hour.
my schwab broker has been wonderful at filling my order at the bid!
I finally jumped in bio_pete. lets see if we can make some money on Javelin!
I don't remember those call/put ratios from the past few months, so can't advise you on whether to wait until expiration or not. May not hurt to wait.
maybe you'll get bullish enough to take a small position!
Nerf, fyi zipjet already has a signficant long rprx position, and I'm sure at much cheaper prices that $13's.
Hang loose!
http://www.investorshub.com/boards/replies.asp?msg=19414126
I couldn't agree more. We are still seeing a large number of pharma partnership deals, and rich ones like the ALNY the other day, as well as pharma and biotech buyouts of little companies like RPRX.
RPRX volume the past 3 days:
ranged between 38-48k shares, 3-4x below the daily average.
interesting, and I see the current bid on the stock moved up 2 cents above the high for the day at 13.09. 13.11 x 13.15
no one is selling. ;) buyers will have to move the price up to get shares imo
Nebido -- yes, IDEV is their trading symbol. Nebido is a testosterone injection I believe (see info below from IDEV site), and imo Androxal drug trumps this drug due to its adverse side-effects over time if I remember the cons correctly from rfj and dewophile.
http://www.indevus.com/site/index.php?option=com_content&task=view&id=26&Itemid=40
NEBIDO is a novel, long-acting injectable testosterone preparation for the treatment of male hypogonadism. NEBIDO is expected to be the first three-month testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Schering AG, Germany, in July 2005. Recently approved and launched in Europe, NEBIDO has a substantial data package which the Company will leverage in its U.S. development activities. In March 2006, the Company announced that the U.S. Food and Drug administration (FDA) had accepted its IND for the Phase III pharmacokinetic study of NEBIDO. A New Drug Application is expected to be filed with the FDA in the second quarter of 2007.
On March 26, 2007, the Company provided an update on its' Phase III pharmacokinetic study of NEBIDO. The Phase III pharmacokinetic trial is an ongoing, randomized open-label (unblinded) study scheduled to conclude the key pharmacokinetic evaluations of total serum testosterone concentrations following treatment with NEBIDO. The Company stated that based on the preliminary data, it is highly likely that at least 75% of patients in the 1000 mg arm will achieve a Cavg within the normal range. Further, no patients in the 1000 mg arm exceeded a concentration level of 2500 ng/dL; four of 97 (4.1%) patients had a peak level over 1800 ng/dL; and 10 of 97 (10.3%) patients had a peak level exceeding 1500 ng/dL. The duration of time any patient had a concentration over these thresholds was brief.
Additionally, the Company stated that based on the available data of the 750 mg arm, it is likely that at least 75% of patients will achieve a Cavg within the normal range. No patients in the 750 mg arm exceeded a level of either 2500 ng/dL or 1800 ng/dL, and four of 103 (3.9%) patients had a peak level exceeding 1500 ng/dL.
Preliminary safety data indicates that both doses of the drug are well- tolerated when given every 12 weeks. The Company expects to update this preliminary report when the study is completed by the end of May 2007 and expects to release final results of the trial in June 2007 and file a New Drug Application (NDA) with the FDA during the summer of 2007.
Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, muscle loss and weakness, as well as an increased risk of osteoporosis. Today, there are an estimated four to five million men in the U.S. who suffer from hypogonadism. Of this group, approximately five percent are currently receiving treatment with testosterone replacement therapy. The market is highly-under treated and is expected to grow by more than 10% annually. The U.S. market has experienced rapid growth to approximately $490 million in 2005.
Hypogonadism is primarily diagnosed and treated by specialty physicians, specifically urologists and endocrinologists. Routine testing of testosterone levels has become a more common part of men's health evaluations by specialists. The three-month dosing schedule would fit in well with the physician-recommended follow-up of every three months making it convenient for patients receiving treatment. Current treatment options include gels, patches, and injections, the latter of which requires 13-26 injections per year. The Company believes that the unique profile of NEBIDO will present an opportunity in the growing market for testosterone replacement, and that physicians and patients currently using other methods of treatment may be willing to switch to NEBIDO because of the many benefits of three-month dosing, including compliance, convenience, and the maintenance of steady serum levels of testosterone for three months.
LOL bio_pete. On your humor, not the sell off on JAV.
Glad your ISIS is making hay on the Needham strong buy coverage. I still haven't bough JAV yet.....but am close! :)
Question on Proellex and Drug Holiday-
Does anyone know from RPRX presentations or discussion with the CEO whether RPRX is able to use the drug holiday process successfully (no risk of heavy VB during the drug holiday)?
Dewophile, your mention of this asoprisnil made me wonder if RPRX had already crossed the "drug holiday" hurdle successfully.
Thanks for anyone's thoughts on this.
dewophile... fyi, question from RPRX board to you or rfj
http://www.investorshub.com/boards/read_msg.asp?message_id=21032204
thanks!
Correct, but someone is obviously also accumulating these volume sale of shares. Otherwise we'd sink 1/2 a point or more in share price. Once this seller(s) are done I would expect the price to stabliize with an upward bias imo.
Thanks again for your thoughts
How is this so-called "holding down of price" occurring? Good news is that increased volume preceeds price movement, right?
There was an afterhours trade of 4,300 shares at 12.737, and the usual 100 share one too.
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
16:18 $ 12.7431 100
16:01 $ 12.737 4,300
rfj - time to buy JAV? Its getting spanked pretty good today off >5%. Interesting that some fund is dumping after the quarter has ended a week ago. Thoughts? Seems like someone is liquidating their JAV and RPRX today.
thanks. actually trading appears to be heating up as I type!
This is stealth buying imho. It will eventually turn into obvious rally when enough sharks catch wind of the value that RPRX holds.
Meanwhile, I notice your JAV getting some selling today and dipping just below $6. I'm watching! :)
Was this a block buy??
http://finance.yahoo.com/q/bc?s=RPRX&t=1d&l=on&z=m&q=l&c=
10k block buys. sorry, I'm just looking at an intraday volume chart by minute on yahoo finance. however, it appears there is a quiet buyer in the 12.87 range right now, and earlier a 10k bid at $13
bio_pete, interesting trading going on this morning. Looks like the MMs are trying to scrap up shares to fill some 10k or larger block orders. At least rprx is finally starting to get some more interest. If you noticed on Mon and Tues, there was also some block buying going on. It was very measured so that it didn't move the stock price up. The stock price will only move up is a number of very interested and less patient buyers start to jump in.
RPRX Proellex research news: Great results (did any rprx investors here know this was on the radar??) and indication by Joe P. quote where "He further commented `Our developmental portfolio of indications is very full at this time. We believe the opportunity to find a partner in the oncology arena for the breast cancer indication represents a great opportunity for the Company. We therefore plan to explore a potential collaborative relationship with one of the major oncology companies for the breast cancer indication.'
Can only increase positive in the trading volume and price of RPRX this summer imho.
Public release date: 3-Jul-2007
American Association for Cancer Research
From clinical cancer research: rethinking therapeutic cancer vaccine trials
Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient�s immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way"
In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results � or endpoints � of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didn�t achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.
�Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors,� said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. �The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.�
According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of measuring the more subtle systemic effects of immune response, Schlom said.
While there is no conclusive evidence to explain why a vaccine may lead to better patient sur-vival, Schlom believes the evidence suggests that vaccines are, in fact, priming the immune sys-tem. �Vaccines are not passive, they induce a dynamic process of immune response that, in many cases may keep the tumor in check and enhance the effectiveness of subsequent therapies,� Schlom said.
About Therapeutic Cancer Vaccines
Unlike preventative vaccines, like those that protect against human papillomavirus or the flu, therapeutic cancer vaccines are given in the hopes of treating an existing disease. These cancer vaccines generally fall into two categories: cell-based, where vaccines are created using cells from the patient�s own immune system that have been activated to the presence of cancer antigens and delivered back to the patient along with additional proteins that facilitate immune activation; and vector-based, where an engineered virus, or vector, is used to introduce cancer proteins and other molecules to stimulate the immune system. Both approaches are designed to rile the patient�s immune system into attacking tumor cells.
In their review Schlom and his colleagues looked at two cell-based vaccines, Sipuleucel-T (Provenge) and GVAX, as well as three trials using an engineered pox-virus vector. While this review article focuses on prostate cancer vaccines, the researchers consider these trials as exam-ples of ongoing progress in similar vaccine therapies for lymphoma, melanoma, pancreatic, lung and other types of cancer.
###
�Cancer Vaccines: Moving Beyond Current Paradigms,� Jeffrey Schlom, et. al., Clinical Cancer Research, July 1, 2007, Volume 13, No. 13, pages 3776-3782.
+++++++++++++++++++++
reposted from DNDN IV board
http://www1.investorvillage.com/smbd.asp?mb=971&pt=msg&mn=139776
bio_pete, no, that street.com article didn't paint a negative light of rprx necessarily. Joe P. was pretty forward in his quote from back in 2001 regarding why they were not successful w/ the FDA on their previous viagra-like drug (unlike ENCY or others that make excuses). I respect his straight shooter approach, but agree with you that he may need to spend a little more time with outreach on the company's successful development to date.
right now it seems that RPRX is trading in the doldrums. however, I see the same thing happening to many other small biotechs. may just be the summer doldrums as we await news.
I haven't bought any JAV yet, as funds are limited but am continuing to watch it, as well as AIS. thanks!
OT: Thoughts on buying AIS
Hi bio_pete, what is your opinion on the Friday news of share placement by AIS to raise some additional cash? Haven't bought any stock yet but am watching here at/below $1.6's. Your thougths/opinions would be appreciated.
T.i.a., Spartex
Mpower: Question on your forecast.
Why do you feel the stock may close near or above the $13.75 offering price? End of quarter window dressing by funds that bought into the original offering in January?
I noticed a few weeks ago that the float of RPRX was report via yahoo finance as up 1 million shares. Just curious if some of these offered shares were now unrestricted for trading by the buyers??
thanks!
Thanks wisard. I wonder if that was the mm's entire inventory? :) Maybe the recent PR news is finally getting some bigger fish to nibble here.
RPRX opened up 54 cents, $13.31, on a block buy I believe. Any ideas?
glt longs!
Americans making progress managing diabetes:
study By Julie Steenhuysen
2 hours, 33 minutes ago
CHICAGO (Reuters) - Americans appear to be doing a better job of managing diabetes, with more than half of diabetics reaching recommended targets for controlling blood sugar last year, according to a survey published on Saturday.
Just over a third of people had their diabetes well-controlled in 2001, according to a study of lab tests done on more than 4 million people with type 1 and type 2 diabetes.
"Control has gotten better and impressively so, but we are not there yet," said Dr. Francine Kaufman, of the University of Southern California and past president of the American Diabetes Association, who analyzed the data.
Overall, diabetes control between 2001 and 2006 improved by 44 percent, according to the study, which was conducted by lab testing company Quest Diagnostics Inc.
Controlling diabetes is important because the condition can quietly damage blood vessels, leading to loss of toes and limbs, blindness, heart disease and death.
The study found that people with diabetes have a worse time controlling their diabetes in the winter, and that men struggle with it more than women. The results were presented on Saturday at the American Diabetes Association's annual scientific meeting in Chicago.
About 20.8 million Americans have diabetes, which causes about 5 percent of all deaths globally each year. Most have type 2, or adult onset diabetes, in which the body loses its ability to use insulin properly.
The Quest study is based on 22.7 million lab tests that measured the average amount of sugar or glucose in a person's blood between 2001 and 2006.
Called the hemoglobin A1C, the test can show whether a person's blood sugar has been normal or too high over recent weeks.
Kaufman called the test a sort of report card for diabetics, with the goal of having blood sugar levels of less than 7 percent of total hemoglobin -- the main protein in red blood cells.
Some studies have shown that every percentage point drop in hemoglobin A1c cuts a patient's risk of eye, kidney or nerve-related complications by 40 percent.
Kaufman said the problem now is that the rate of improvement appears to have slowed.
"What is really tough is the last decrease in the A1c," she said in a telephone interview. She thinks a lot of the initial decrease in blood sugar levels was related to more patients getting medications, but that will not be enough for many people to get their disease to the target level.
"People with diabetes will have to get out and get walking, lose that 5 to 10 pounds (2 to 5 kg). Just taking a pill and not doing anything else isn't enough," she said.
Kaufman said the study highlighted other trouble spots.
"The group with the overall poorest control are men," she said. "One could presume they are busy trying to get ahead in the workplace and start a family."
It also found diabetics struggle more in the winter.
"People do worse in January, February and March than they do in the summer, probably because we start overeating around Thanksgiving and don't get serious until the sunshine begins," she said.
The problem is that people underestimate the threat of diabetes, which Kaufman said is a big mistake.
Poorly managed type 2 diabetes, the kind linked with obesity and lack of exercise, costs the U.S. health system an extra $22.9 billion a year in direct medical costs, a recent study found.
"This is a life-taking, life-altering disease if you don't manage it," she said.
http://news.yahoo.com/s/nm/20070623/hl_nm/diabetes_control_dc
Link to Dew's post on official termination of Asoprisnil by Bayer.
http://www.investorshub.com/boards/read_msg.asp?message_id=20587109
"Bayer formally kills asoprisnil program"
I guess it wasn't something of significance to the street (and RPRX) as there wasn't any positive response (buying) in RPRX today. In other words, it was already known that asoprisnil program was shelved permanently.
Thanks for the update Dew!
Any REGN news? Up on strong volume. $19 + 0.75
Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Tuesday June 19, 8:40 am ET
Rylomine(TM) Meets Primary Endpoint, Significantly Reduces Postsurgical Orthopedic Pain
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV - News) announced today that its product candidate Rylomine(TM) (intranasal morphine) successfully met its primary clinical endpoint, the Sum of the Pain Intensity Difference (SPID) scores over 0-24 hours postoperatively. In this first of two pivotal Phase 3 studies, patients with moderate-to-severe pain after elective orthopedic surgery were given 7.5 mg Rylomine every hour as needed, 15 mg Rylomine every 3 hours as needed, or 7.5 mg intravenous (IV) morphine every 3 hours as needed. Patients in each of the three active treatment groups had significantly better (p less than .01 or less) SPID scores over 24 hours than the corresponding placebo groups.
"Parenteral morphine is the gold standard for postoperative analgesia," commented Dr. Daniel B. Carr, CEO and CMO of Javelin Pharmaceuticals. "Today's gratifying results extend our prior positive study findings showing that Rylomine is a simple, effective alternative to more complex, cumbersome and costly methods of postoperative opioid analgesia. We look forward to continuing the development of this innovative product candidate."
There were no serious adverse events related to the study drug. Local adverse events associated with nasal administration (bad taste, throat irritation, instillation site reaction, nasal erythema, nasal irritation) were more common with Rylomine or intranasal placebo than the intravenous morphine groups. General systemic adverse events related to active drug were similar across morphine treatment groups regardless of route of administration and consistent with morphine's known pharmacologic effects (dizziness, nausea, transient decreased oxygen saturation, and vomiting).
Full analyses of the data are ongoing and will be reported when available.
About the Study
This study, termed MOR-003, involved 278 randomized patients with moderate to severe post-surgical pain enrolled at 7 sites in the United States. These patients received either 7.5 mg Rylomine every hour as needed, 15 mg Rylomine every three hours as needed, 7.5 mg IV morphine, or matching placebos. In this "blinded" study, patients received treatments of which the identity (active or placebo) was not known by either the Investigator or the patient, although patients did know whether they were receiving intravenous or intranasal treatment.
About Rylomine(TM)
Rylomine is a patient-controlled nasal spray that delivers a single metered dose of morphine, an opioid analgesic used for the treatment of moderate-to-severe pain. After use, a negligible amount of morphine remains in the dispenser, reducing the risk of scavenging and abuse of discarded devices. Data from clinical studies have demonstrated that Rylomine has similar efficacy to an infusion of intravenous morphine.
Parenteral morphine is the standard of care for management of acute moderate-to-severe pain, especially after surgery, when analgesic requirements vary between individuals and often fluctuate even in the same patient. IV morphine analgesia has rapid onset, proven efficacy, can accommodate variations in analgesic demand, and has side effects that are well understood by medical personnel. Morphine, like many drugs, is poorly absorbed across mucosal barriers and, in particular, the nasal membrane. Javelin's proprietary technology allows for nasal delivery of predictable therapeutic blood levels of morphine. The key to this technology is ChiSys(TM), a carbohydrate polymer that, while pharmaceutically inert by itself, enhances the absorption of compounds across mucosal membranes, such as in the nasal cavity. The contribution of ChiSys(TM) to enhancing mucosal drug absorption reflects several factors including its potent mucoadhesive property, which prevents drug washout. Rylomine is a novel formulation of morphine and ChiSys(TM) packaged in a single unit-dose nasal spray. Worldwide, no comparable formulation of morphine is available.
About Javelin Pharmaceuticals, Inc.
With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit www.javelinpharmaceuticals.com.
Forward-looking Statement
This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA (and foreign equivalent) review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
Contact:
Javelin Pharmaceuticals, Inc.
Investor Relations & Media
Rick Pierce, 617-349-4500
VP Investor Relations
rpierce@javelinpharmaceuticals.com
or
Corporate Communications
June Gregg, 617-349-4500
jgregg@javelinpharmaceuticals.com
Fax: 617-349-4505
--------------------------------------------------------------------------------
Source: Javelin Pharmaceuticals, Inc.
http://biz.yahoo.com/bw/070619/20070619005272.html?.v=1
Mpower, nice sensible post. EOM
OT: Selling puts on AMGN and other large caps - this is from Barron's.
A Strategy Built for Bulls
By STEVEN M. SEARS
OPPORTUNITY OFTEN RESIDES between contradiction and fear.
As bond yields rise and the volatility of many equity options floats higher in anticipation that stocks may go lower, a paradoxical trade is emerging, just as the second-quarter earnings season begins. Goldman Sachs' wily options strategists recommend selling put options to express a bullish view on mega-cap stocks, even as some investors fret that stocks will slip during the lazy days of summer.
The rationale for this seemingly contrarian trade is a market call by Goldman's portfolio strategist, who thinks stocks may advance into the summer because investor expectations are too conservative, especially for big companies. Sound familiar? First-quarter profits also were expected to be lackluster. But they beat expectations, helping to propel stocks to new highs.
Many stocks have recovered nicely since the recent 3% decline in the S&P 500, yet Goldman's options strategists, Maria Grant and John Marshall, have identified 15 mega-caps with elevated options prices, and strong fundamentals that are worth betting on. After screening their universe of liquid options -- about 350 names -- they found that the implied volatility of stocks with market capitalizations above $40 billion were significantly higher than that of smaller issues. These stocks' implied volatility -- essentially, price -- had risen, on average, 5.1% in the previous week, versus 2.7% for smaller stocks. Implied volatility also is higher for mega-caps than it is elsewhere in the market.
To benefit from these discrepancies, the strategists recommend selling three-month puts on Target (TGT), AT&T (T), PepsiCo (PEP), Coca-Cola (KO), Comcast (CMCSA), Oracle (ORCL), Sears (S), IBM (IBM), Wells Fargo (WFC), Merrill Lynch (MER), Johnson & Johnson (JNJ), Morgan Stanley (MS), Amgen (AMGN), General Electric (GE), and Disney (DIS).
To qualify for the list, stocks had to be rated Buy by Goldman's equity analysts, have three-month volatility among the most expensive of the past year and boast a market value above $40 billion. Target's three-month options volatility, for example, is at its highest level of the year, and AT&T, Pepsi and Coca-Cola options aren't far behind.
Goldman's portfolio strategist, David Kostin, believes second- quarter consensus earnings estimates are too low. He views large-caps as more attractive than small-caps, in part because big stocks have about double the exposure to fast-growing international markets, and this helped them report better-than-expected first-quarter net. Moreover, large-caps are less sensitive to interest rates and widening credit spreads, owing to their generally well-managed balanced sheets. In addition, based on measures such as price-to-earnings and price-to-book ratios, large-caps are at the bottom of their 20-year average, and hedge funds "have recently began to shift" into large- and mid-cap stocks and away from small-caps.
If the trades work, investors will be in for an end of summer treat. If not, they'll get a chance to own some good stocks, and that's not bad either.
--------------------------------------------------------------------------------
io_io, thanks for your reply. I realize we differ on opinions whether TA has an effect on trading of biotechs like rprx, however the chart I showed you speaks for itself in terms of support and resistance levels. ;)
Investor Business Daily now has RPRX as a 'C' for accumulation; it was an A two weeks ago, so there has been some distribution. Hope it moves back up to B and higher shortly.
I would also like to see rprx above their 50 dma on Monday.....and some bargain buying by longs.
good luck
TA Answers to io_io's Qs
1. Yes I believe TA can still apply even for thinly traded biotechs like RPRX. When RPRX broke down after their secondary it did settle near the 200 exp day moving avg before ramping back up. And after breaking through 50 dma that became its new support. (see link below)
2. Yes, same answer as in #1. Regardless, as with any stock, PR of significant news can move a stock up or down regardless of technicals.
http://finance.yahoo.com/q/ta?s=RPRX&t=3m&l=on&z=m&q=b&p=m200,b,e50,e100,e200&am....
Bio_pete, I agree with you. Also, do you have any insights on what David M. may have said after the recent Proellex endo news, and selloff??
In addition to the OE, I believe some of the hedge funds are just locking in their gains after buying the stock in the 10's region and getting both the Androxal and Proellex news. Too bad it is happening, but they play the quarterly performance game.
Happy Father's Day to all Fathers!
Jonathan, the chart is there if you wait a few seconds. it will pop up below Dead's post. I hope he isn't right about the negative trend direction for RPRX but one can't consider it out of the possibilities.